NCT03002389View on ClinicalTrials.gov

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

November 5, 2017

Primary Completion Date

December 31, 2023

Study Completion Date

January 31, 2028

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Anoro Ellipta

inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days

DRUG

Arnuity Ellipta

inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days

Trial Locations (1)

22947

Roselove NUNOO-ASARE, Keswick

All Listed Sponsors
lead

University of Virginia

OTHER